1158680-88-6

Basic information

• Product Name: 6-broMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
• Synonyms: 6-broMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
• CAS NO: 1158680-88-6
• Molecular Formula: C₁₂H₁₃BrN₂O
• Molecular Weight: 281.14842
• Mol File: 1158680-88-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 54-55 °C
• Boiling Point: 405.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.60±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.18±0.30(Predicted)
• CAS DataBase Reference: 6-broMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(1158680-88-6)
• EPA Substance Registry System: 6-broMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(1158680-88-6)

Safety Data

• Hazardous Substances Data: 1158680-88-6(Hazardous Substances Data)

Usage

General Description

6-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole is a chemical compound with the molecular formula C15H17BrN2O. It is an indazole derivative with a bromine atom and a tetrahydro-2H-pyran-2-yl group attached to the indazole ring. 6-broMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole may have potential applications in medicinal and pharmaceutical research due to its unique structure and potential pharmacological properties. It is important to handle this compound with care and follow proper safety precautions due to its potential hazards and reactivity. Further research and studies may be necessary to fully understand the properties and potential uses of 6-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole.

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 79762-54-2 6-bromo-1H-indazole 

Downstream Products

• 1158680-98-8 1-(tetrahydro-2H-pyran-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 1421503-55-0 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazol-3-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester 
• 1421503-50-5 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1-(tetrahydro-pyran-2-yl)-1H-indazole 
• 1421503-49-2 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1H-indazole 
• 1421503-48-1 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1H-indazole 

Relevant articles and documents

Synthesis and Activity Evaluation of Nasopharyngeal Carcinoma Inhibitors Based on 6-(Pyrimidin-4-yl)-1H-indazole

Human nasopharyngeal carcinoma is a common head and neck malignancy with high incidence in Southeast Asia and Southern China. It is necessary to develop safe, effective and inexpensive anticancer agents to improve the therapeutics of patients with nasopharyngeal carcinoma. A series of small molecular compounds based on 6-(pyrimidin-4-yl)-1H-indazole were synthesized and evaluated for antiproliferative activities against human nasopharyngeal carcinoma cell lines SUNE1. Compounds 6b, 6c, 6e and 6l showed potent antiproliferative activities similar to positive control drug cisplatin in vitro with lower nephrotoxicity than it. N-[4-(1H-Indazol-6-yl)pyrimidin-2-yl]benzene-1,3-diamine (6l) was selected for further study. It was found that 6l induced mitochondria-mediated apoptosis and G2/M phase arrest in SUNE1 cells. Furthermore, compound 6l at 10 mg/kg can suppress the growth of an implanted SUNE1 xenograft with a TGI% (tumor growth inhibition) value of 50 % and did not cause serious side effects in BALB/c nude mice. This study suggests that 6-(pyrimidin-4-yl)-1H-indazole derivatives are a series of small molecule compounds with anti-nasopharyngeal carcinoma activities.

FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND

The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.

COMPOUNDS

Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).